Oruka Therapeutics ORKA
United StatesHealthcare · BiotechnologyUSD
155.00 USD (+95.0%)
12 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Oruka Therapeutics is a development-stage biotechnology company that generates no revenue and whose value depends on the progress of its drug candidates, subject to regulatory approval.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Favourable backdrop8.7
- ✕Demanding valuation0.3
- ✕Little competitive advantage0.5
- ✕Little or no dividend0.5
AI analysis
bottom line, main risk, context and newsThe risk of dilution and clinical failure outweighs any potential, and the current valuation already discounts a success scenario that is not guaranteed.
Oruka Therapeutics is a pre-revenue biotech with an already strained balance sheet (net debt/EBITDA of 5.62x, 0% operating margin) and an ROE of -18.23%, whose value depends on future clinical success that the market is pricing with 277% 12-month momentum, a position that seems unsustainable without additional funding.
The main risk is dependence on a single clinical-stage drug candidate: failure in any trial would destroy value, and 5.62x net debt/EBITDA with no revenue forces future dilution that penalizes shareholders.
Context and risks
Pre-clinical or early-stage biotech with no revenue and a 0% operating margin, implying total dependence on external financing and regulatory approval of its candidates. The business model risk is extreme: value depends on a single drug or platform that can fail at any trial phase, and net debt of 5.62x EBITDA (even with negative EBITDA) reflects an already strained balance sheet. US governance is solid, but FDA regulatory risk is inherent to the sector.
Is Oruka Therapeutics stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 4.4 | 4.1 | +6% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 155.00 USD, +95.0% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −27.8
- EV / EBITDA
- −28.4
- Price / book
- 4.4
- Market cap
- 5.3B USD
- Enterprise value
- 4.4B USD
Profitability
- ROE
- −18.2%
- ROA
- −13.0%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −65.0M USD
- FCF yield
- −1.2%
Solvency
- Total debt
- 2.5M USD
- Net debt
- −871.0M USD
- Cash
- 873.6M USD
- EBITDA
- −154.9M USD
- Net debt / EBITDA
- 5.62
- Debt / equity
- 0.23
- Current ratio
- 38.51
- Quick ratio
- 38.03
Growth
- EPS (TTM)
- −2.04 USD
- EPS (forward)
- −2.86 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- −0.11
- Analyst consensus
- Strong buy (12)
- Target price
- 155.00 USD
- 52-week range
- 21.66 – 115.52
Recent news
All ORKA news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Oruka Therapeutics
Is Oruka Therapeutics stock cheap or expensive?
Valuation score: 0.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 155.00 USD, +95.0% versus the price. This is not investment advice.
What score does Oruka Therapeutics get on MeridIAn Screener?
It scores 2.9 out of 10, rank 2,094 of 2,130 (better than 2% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Valuation (0.3). Analysis of 08/10/2026.
How much is Oruka Therapeutics worth on the stock market?
Its market capitalisation is 5.3B USD and its enterprise value, debt included, is 4.4B USD.
How much debt does Oruka Therapeutics have?
It has more cash than debt: net cash of 871.0M USD.
Does Oruka Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Oruka Therapeutics stock performed over the last year?
It has risen 224.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 21.66 and 115.52 USD. Past performance does not guarantee future results.
What do analysts think of Oruka Therapeutics?
12 analysts cover it; their average recommendation is “Strong buy” and their average target is 155.00 USD (+95.0% versus the price). It is an estimate, not market data.